145 results on '"Leccisotti, Lucia"'
Search Results
102. Physiological Activity of Spinal Cord in Children
- Author
-
Taralli, Silvia, primary, Leccisotti, Lucia, additional, Mattoli, Maria Vittoria, additional, Castaldi, Paola, additional, de Waure, Chiara, additional, Mancuso, Agostino, additional, and Rufini, Vittoria, additional
- Published
- 2015
- Full Text
- View/download PDF
103. Transposition of the Great Arteries
- Author
-
Leccisotti, Lucia, primary, Bruno, Isabella, additional, Stefanelli, Antonella, additional, Caldarella, Carmelo, additional, and Giordano, Alessandro, additional
- Published
- 2013
- Full Text
- View/download PDF
104. Which is the optimal acquisition time for FDG PET/CT imaging in patients with infective endocarditis?
- Author
-
Caldarella, Carmelo, primary, Leccisotti, Lucia, additional, Treglia, Giorgio, additional, and Giordano, Alessandro, additional
- Published
- 2012
- Full Text
- View/download PDF
105. Usefulness of 18F-FDG PET/CT in Evaluating Disease Activity at Different Times in a Patient With Chronic Periaortitis
- Author
-
Treglia, Giorgio, primary, Stefanelli, Antonella, additional, Mattoli, Maria Vittoria, additional, Leccisotti, Lucia, additional, Muoio, Barbara, additional, and Bertagna, Francesco, additional
- Published
- 2012
- Full Text
- View/download PDF
106. Cardiac Metastases of Ewing Sarcoma Detected by 18F-FDG PET/CT
- Author
-
Coccia, Paola, primary, Ruggiero, Antonio, additional, Rufini, Vittoria, additional, Maurizi, Palma, additional, Attinà, Giorgio, additional, Marano, Riccardo, additional, Natale, Luigi, additional, Leccisotti, Lucia, additional, Calcagni, Maria L., additional, and Riccardi, Riccardo, additional
- Published
- 2012
- Full Text
- View/download PDF
107. Usefulness of F-18 FDG PET/CT in the Follow-up of POEMS Syndrome After Autologous Peripheral Blood Stem Cell Transplantation
- Author
-
Stefanelli, Antonella, primary, Treglia, Giorgio, additional, Leccisotti, Lucia, additional, Laurenti, Luca, additional, Luigetti, Marco, additional, Sabatelli, Mario, additional, and Giordano, Alessandro, additional
- Published
- 2012
- Full Text
- View/download PDF
108. The role of 18F-FDG PET/CT in the management of large-vessel vasculitis: applications and limitations in clinical practice
- Author
-
Mattoli, Maria V., primary, Treglia, Giorgio, primary, Leccisotti, Lucia, primary, and Giordano, Alessandro, primary
- Published
- 2012
- Full Text
- View/download PDF
109. Positron Emission Tomography in Acute Coronary Syndromes
- Author
-
Galiuto, Leonarda, primary, Paraggio, Lazzaro, additional, De Caterina, Alberto R., additional, Fedele, Elisa, additional, Locorotondo, Gabriella, additional, Leccisotti, Lucia, additional, Giordano, Alessandro, additional, Rebuzzi, Antonio G., additional, and Crea, Filippo, additional
- Published
- 2011
- Full Text
- View/download PDF
110. Early evaluation of cerebral metabolic rate of glucose (CMRglu) with 18F-FDG PET/CT and clinical assessment in idiopathic normal pressure hydrocephalus (INPH) patients before and after ventricular shunt placement: preliminary experience
- Author
-
Calcagni, Maria Lucia, primary, Lavalle, Mariadea, additional, Mangiola, Annunziato, additional, Indovina, Luca, additional, Leccisotti, Lucia, additional, De Bonis, Pasquale, additional, Marra, Camillo, additional, Pelliccioni, Armando, additional, Anile, Carmelo, additional, and Giordano, Alessandro, additional
- Published
- 2011
- Full Text
- View/download PDF
111. Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria
- Author
-
Caulo, Andrea, primary, Mirsadraee, Saeed, additional, Maggi, Fabio, additional, Leccisotti, Lucia, additional, van Beek, Edwin J. R., additional, and Bonomo, Lorenzo, additional
- Published
- 2011
- Full Text
- View/download PDF
112. Restaging Locally Advanced Rectal Cancer with MR Imaging after Chemoradiation Therapy
- Author
-
Barbaro, Brunella, primary, Vitale, Renata, additional, Leccisotti, Lucia, additional, Vecchio, Fabio M., additional, Santoro, Luisa, additional, Valentini, Vincenzo, additional, Coco, Claudio, additional, Pacelli, Fabio, additional, Crucitti, Antonio, additional, Persiani, Roberto, additional, and Bonomo, Lorenzo, additional
- Published
- 2010
- Full Text
- View/download PDF
113. Authors’ Response
- Author
-
Barbaro, Brunella, primary, Vitale, Renata, additional, Leccisotti, Lucia, additional, Vecchio, Fabio M., additional, Santoro, Luisa, additional, Valentini, Vincenzo, additional, Coco, Claudio, additional, Pacelli, Fabio, additional, Crucitti, Antonio, additional, Persiani, Roberto, additional, and Bonomo, Lorenzo, additional
- Published
- 2010
- Full Text
- View/download PDF
114. Relationship Between Regional Myocardial Oxygenation and Perfusion in Patients With Coronary Artery Disease
- Author
-
Karamitsos, Theodoros D., primary, Leccisotti, Lucia, additional, Arnold, Jayanth R., additional, Recio-Mayoral, Alejandro, additional, Bhamra-Ariza, Paul, additional, Howells, Ruairidh K., additional, Searle, Nick, additional, Robson, Matthew D., additional, Rimoldi, Ornella E., additional, Camici, Paolo G., additional, Neubauer, Stefan, additional, and Selvanayagam, Joseph B., additional
- Published
- 2010
- Full Text
- View/download PDF
115. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction
- Author
-
Cook, Stuart A., primary, Varela-Carver, Anabel, additional, Mongillo, Marco, additional, Kleinert, Christina, additional, Khan, Muhammad T., additional, Leccisotti, Lucia, additional, Strickland, Nicola, additional, Matsui, Takashi, additional, Das, Saumya, additional, Rosenzweig, Anthony, additional, Punjabi, Prakash, additional, and Camici, Paolo G., additional
- Published
- 2009
- Full Text
- View/download PDF
116. Blood oxygen level-dependent MRI in patients with coronary artery disease and normal volunteers: a validation study against PET
- Author
-
Karamitsos, Theodoros D, primary, Recio-Mayoral, Alejandro, additional, Arnold, Jayanth R, additional, Leccisotti, Lucia, additional, Bhamra-Ariza, Paul, additional, Howells, Ruairidh K, additional, Searle, Nick, additional, Robson, Matthew D, additional, Rimoldi, Ornella E, additional, Camici, Paolo G, additional, Neubauer, Stefan, additional, and Selvanayagam, Joseph B, additional
- Published
- 2009
- Full Text
- View/download PDF
117. Abstract 2240: T2-Prepared Steady-State Free-Precession Blood Oxygenation Level-Dependent MRI in Patients with Coronary Artery Disease and Normal Volunteers: Validation against PET
- Author
-
Karamitsos, Theodoros D, primary, Recio-Mayoral, Alejandro, additional, Arnold, Jayanth R, additional, Leccisotti, Lucia, additional, Bhamra-Ariza, Paul, additional, Howells, Ruairidh K, additional, Searle, Nick, additional, Robson, Matthew D, additional, Rimoldi, Ornella E, additional, Camici, Paolo G, additional, Neubauer, Stefan, additional, and Selvanayagam, Joseph B, additional
- Published
- 2008
- Full Text
- View/download PDF
118. Hemodialysis-Induced Cardiac Dysfunction Is Associated with an Acute Reduction in Global and Segmental Myocardial Blood Flow
- Author
-
McIntyre, Christopher W., primary, Burton, James O., additional, Selby, Nicholas M., additional, Leccisotti, Lucia, additional, Korsheed, Shvan, additional, Baker, Christopher S.R., additional, and Camici, Paolo G., additional
- Published
- 2007
- Full Text
- View/download PDF
119. Abstract 3357: Haemodialysis Induced Contractile Dysfunction is Associated with Acute and Reversible Reduction in Global and Segmental Myocardial Blood Flow
- Author
-
Burton, James, primary, Selby, Nicholas, additional, Leccisotti, Lucia, additional, Korsheed, Shvan, additional, McIntyre, Christopher, additional, and Camici, Paolo, additional
- Published
- 2007
- Full Text
- View/download PDF
120. The predictive value of F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy.
- Author
-
Leccisotti, Lucia, Gambacorta, Maria, Waure, Chiara, Stefanelli, Antonella, Barbaro, Brunella, Vecchio, Fabio, Coco, Claudio, Persiani, Roberto, Crucitti, Antonio, Tortorelli, Antonino, Giordano, Alessandro, and Valentini, Vincenzo
- Subjects
CANCER chemotherapy ,TUMOR treatment ,ADENOCARCINOMA ,PREOPERATIVE period ,HISTOPATHOLOGY - Abstract
Purpose: To evaluate whether metabolic changes in the primary tumour during and after preoperative radiochemotherapy (RCT) can predict the histopathological response in patients with locally advanced rectal cancer as well as disease-free survival (DFS) and overall survival (OS). Methods: Consecutive patients with cT2-4 N0-2 rectal adenocarcinoma were included. F-FDG PET/CT was performed at baseline, at the end of the second week of RCT (early PET/CT) and before surgery (late PET/CT). The PET/CT results were compared with histopathological data (ypT0 N0 vs. ypT1-4 N0-2 as well as TRG1 vs.TRG2-5) and survival. Results: The study included 126 patients. Among 124 patients in whom TNM classification was available, 28 (22.6 %) were ypT0 N0, and among all 126 patients, 31 (24.6 %) were TRG1. The areas under the curve of the early response index (RI) for identifying non-complete pathological response (non-cPR) were 0.74 (95 % CI 0.61 - 0.87) for ypT1-4 N0-2 patients and 0.75 (95 % CI 0.62 - 0.88) for TRG2-5 patients. The optimal cut-off for differentiating patients with non-cPR and cPR was found to be a reduction of 61.2 % (83.1 % sensitivity and 65 % specificity in ypT1-4 N0-2 patients; 85.4 % sensitivity and 65.2 % specificity in TRG2-5 patients). The optimal cut-off for late RI could not be found. The qualitative analysis of images obtained after RCT demonstrated 81.5 % sensitivity and 61.3 % specificity in predicting TRG2-5. After a median follow-up of 68 months, the low number of patients with local/distant recurrence or who had died did not allow the value of PET/CT for predicting DFS and OS to be calculated. Conclusion: The early assessment of response to RCT by F-FDG PET/CT can predict non-cPR allowing practical modification of preoperative treatment. Conversely, late RI is not sufficiently accurate for guiding the decision as to whether local excision or even observation is appropriate in an individual patient. Qualitative analysis of late PET/CT images is also not sensitive enough alone to rule out the presence of residual disease. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
121. [¹⁸F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience.
- Author
-
Bertagna F, Treglia G, Leccisotti L, Bosio G, Motta F, Giordano A, Giubbini R, Bertagna, Francesco, Treglia, Giorgio, Leccisotti, Lucia, Bosio, Giovanni, Motta, Federica, Giordano, Alessandro, and Giubbini, Raffaele
- Abstract
Purpose: The aim of our study was to assess the feasibility and usefulness of 2-[(18)F]-fluoro-2-deoxy-D: -glucose positron emission tomography computed tomography ([(18)F]FDG-PET/CT) in patients affected by retroperitoneal fibrosis.Materials and Methods: We retrospectively evaluated 25 patients studied in two centers: 18 underwent [(18)F]FDG-PET/CT as initial evaluation, three during follow-up, three during steroid therapy, and one to re-evaluate the disease. Among the group who underwent initial evaluation, ten underwent a second [(18)F]FDG-PET/CT after steroid therapy.Results: [(18)F]FDG-PET/CT was positive in 18 patients and negative in seven. Among the ten patients who underwent a second study after steroid therapy, six showed complete metabolic response, three partial response, and one no significant maximum standardized uptake value (SUV(max)) reduction.Conclusion: Our preliminary results show that [(18)F]FDG-PET/CT is feasible and suitable for evaluating retroperitoneal fibrosis and is useful in assessing therapy response. Larger studies are desirable to confirm these findings and to determine the appropriate position of [(18)F]FDG-PET/CT in the diagnostic flow chart for this disease. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
122. Early evaluation of cerebral metabolic rate of glucose (CMRglu) with F-FDG PET/CT and clinical assessment in idiopathic normal pressure hydrocephalus (INPH) patients before and after ventricular shunt placement: preliminary experience.
- Author
-
Calcagni, Maria, Lavalle, Mariadea, Mangiola, Annunziato, Indovina, Luca, Leccisotti, Lucia, Bonis, Pasquale, Marra, Camillo, Pelliccioni, Armando, Anile, Carmelo, and Giordano, Alessandro
- Subjects
GLUCOSE metabolism ,HYDROCEPHALUS ,POSITRON emission tomography ,NEUROPSYCHOLOGICAL tests ,NEUROSURGERY ,PATIENTS - Abstract
Purpose: We evaluated the relationships between the cerebral metabolic rate of glucose (CMRglu) measured by dynamic F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and the clinical and neuropsychological assessment before and after the surgical procedure in idiopathic normal pressure hydrocephalus (INPH) patients. Methods: Eleven selected INPH patients underwent clinical assessment (modified Rankin scale, Krauss scale, Larsson categorization system and Stein-Langfitt scale), cognitive evaluation (Mini-Mental State Examination, MMSE) and dynamic F-FDG PET/CT scan 3 days before and 1 week after ventricular shunt placement. Results: After shunting, the global CMRglu significantly increased (2.95 ± 0.44 vs 4.38 ± 0.68, p = 10) in all INPH patients with a mean percentage value of 48.7%. After shunting, no significant change was found in the Evans ratio whereas a significant decrease in all clinical scale scores was observed. Only a slight reduction in the MMSE was found. After shunting, a significant correlation between the global CMRglu value and clinical assessment was found ( R = 0.75, p = 0.024); indeed all clinical scale scores varied (decreasing) and the CMRglu value also varied (increasing) in all INPH patients. Conclusion: Our preliminary data show that changes in the CMRglu are promptly reversible after surgery and that there is a relationship between the early metabolic changes and clinical symptoms, independently from the simultaneous changes in the ventricular size. The remarkable and prompt improvement in the global CMRglu and in symptoms may also have important implications for the current concept of 'neuronal plasticity' and for the cells' reactivity in order to recover their metabolic function. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
123. 18 F-fluoro-deoxy-glucose focal uptake in very small pulmonary nodules: fact or artifact? Case reports.
- Author
-
Calcagni, Maria Lucia, Taralli, Silvia, Maggi, Fabio, Rufini, Vittoria, Treglia, Giorgio, Leccisotti, Lucia, Bonomo, Lorenzo, and Giordano, Alessandro
- Subjects
POSITRON emission tomography ,MEDICAL imaging systems ,GLUCOSE ,BRONCHIOLES ,ELECTRONIC collimation ,DIAGNOSTIC imaging centers - Abstract
Background:
18 F-fluoro-deoxy-glucose (18 F-FDG) positron emission tomography integrated/combined with computed tomography (PET-CT) provides the best diagnostic results in the metabolic characterization of undetermined solid pulmonary nodules. The diagnostic performance of18 F-FDG is similar for nodules measuring at least 1 cm and for larger masses, but few data exist for nodules smaller than 1 cm. Case presentation: We report five cases of oncologic patients showing focal lung18 F-FDG uptake on PET-CT in nodules smaller than 1 cm. We also discuss the most common causes of18 F-FDG false-positive and false-negative results in the pulmonary parenchyma. In patient 1, contrast-enhanced CT performed 10 days before PET-CT did not show any abnormality in the site of uptake; in patient 2, high-resolution CT performed 1 month after PET showed a bronchiole filled with dense material interpreted as a mucoid impaction; in patient 3, contrast-enhanced CT performed 15 days before PET-CT did not identify any nodules; in patients 4 and 5, contrast-enhanced CT revealed a nodule smaller than 1 cm which could not be characterized. The18 F-FDG uptake at follow-up confirmed the malignant nature of pulmonary nodules smaller than 1 cm which were undetectable, misinterpreted, not recognized or undetermined at contrast-enhanced CT. Conclusion: In all five oncologic patients,18 F-FDG was able to metabolically characterize as malignant those nodules smaller than 1 cm, underlining that:18 F-FDG uptake is not only a function of tumor size but it is strongly related to the tumor biology; functional alterations may precede morphologic abnormalities. In the oncologic population, especially in higher-risk patients, PET can be performed even when the nodules are smaller than 1 cm, because it might give an earlier characterization and, sometimes, could guide in the identification of alterations missed on CT. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
124. Il contributo della PET/TC con 18F-FDG nelle vasculiti dei grossi vasi: applicazioni e limiti della metodica nella pratica clinica.
- Author
-
Mattoli, Maria V., Treglia, Giorgio, Leccisotti, Lucia, and Giordano, Alessandro
- Abstract
Copyright of Italian Journal of Medicine is the property of PAGEPress and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2011
- Full Text
- View/download PDF
125. Usefulness of F-FDG PET/CT in Evaluating Disease Activity at Different Times in a Patient With Chronic Periaortitis.
- Author
-
Treglia, Giorgio, Stefanelli, Antonella, Mattoli, Maria, Leccisotti, Lucia, Muoio, Barbara, and Bertagna, Francesco
- Published
- 2013
- Full Text
- View/download PDF
126. Cardiac Metastases of Ewing Sarcoma Detected by 18F-FDG PET/CT.
- Author
-
Coccia, Paola, Ruggiero, Antonio, Rufini, Vittoria, Maurizi, Palma, Attinà, Giorgio, Marano, Riccardo, Natale, Luigi, Leccisotti, Lucia, Calcagni, Maria L., and Riccardi, Riccardo
- Published
- 2012
- Full Text
- View/download PDF
127. 11C-Methionine-Avid Plasmablastic Lymphoma.
- Author
-
Annunziata, Salvatore, Cuccaro, Annarosa, Caldarella, Carmelo, Leccisotti, Lucia, and Hohaus, Stefan
- Published
- 2017
- Full Text
- View/download PDF
128. The Role of Fibroblast Activation Protein Inhibitor Positron Emission Tomography in Inflammatory and Infectious Diseases: An Updated Systematic Review.
- Author
-
Albano, Domenico, Rizzo, Alessio, Slart, Riemer H. J. A., Hess, Søren, Noriega-Álvarez, Edel, Wakfie-Corieh, Cristina Gamila, Leccisotti, Lucia, Glaudemans, Andor W. J. M., Gheysens, Olivier, and Treglia, Giorgio
- Subjects
- *
POSITRON emission tomography , *COMMUNICABLE diseases , *INTERSTITIAL lung diseases , *CROHN'S disease , *COMPUTED tomography - Abstract
The role of fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) is emerging for the assessment of non-oncological diseases, such as inflammatory and infectious diseases, even if the evidence in the literature is still in its initial phases. We conducted a systematic search of Scopus, PubMed/MEDLINE, Embase, and Cochrane library databases for studies published before 31 December 2023 reporting infectious and inflammatory disease imaging with FAPI PET/CT. We included twenty-one studies for a total of 1046 patients. The most frequent disease studied was lung interstitial disease, investigated in six studies for a total of 200 patients, followed by bone and joint diseases in two studies and 185 patients, IgG4-related disease in 53 patients, and Crohn's disease in 30 patients. Despite the heterogeneity of studies in terms of study design and technical features, FAPI PET/CT showed a high detection rate and diagnostic role. Moreover, when compared with 2-[18F]FDG PET/CT (n = 7 studies), FAPI PET/CT seems to have better diagnostic performances. The presence of chronic inflammation and tissue remodeling, typical of immune-mediated inflammatory conditions, may be the underlying mechanism of FAPI uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
129. Role of 18 F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma: Current Evidence and Innovative Applications.
- Author
-
Caldarella, Carmelo, De Risi, Marina, Massaccesi, Mariangela, Miccichè, Francesco, Bussu, Francesco, Galli, Jacopo, Rufini, Vittoria, and Leccisotti, Lucia
- Subjects
- *
HEAD & neck cancer diagnosis , *HEAD & neck cancer treatment , *SQUAMOUS cell carcinoma , *RADIOPHARMACEUTICALS , *MEDICAL technology , *RADIOTHERAPY , *COMPUTED tomography , *DEOXY sugars , *RADIOMICS , *POSITRON emission tomography , *TREATMENT effectiveness , *MAGNETIC resonance imaging , *COMPUTERS in medicine , *TUMOR classification , *MACHINE learning , *NECK surgery - Abstract
Simple Summary: Among head–neck tumors, squamous cell carcinoma is the most frequent histotype and includes a range of malignancies with different sites of origin as well as different therapeutic strategies and clinical outcomes. In daily practice, patients with head–neck squamous cell carcinoma are seen in various clinical settings, requiring a multidisciplinary approach to therapeutic decisions and clinical care. 18F-FDG PET/CT plays a well-defined role in the management of these tumors for pre-treatment staging and radiotherapy planning as well as treatment-response assessment and post-therapy follow-up. This paper is an overview of the standard use of 18F-FDG PET/CT in the various clinical scenarios of head–neck squamous cell carcinoma. Also, emerging applications will be reviewed, including the use of radiopharmaceuticals other than 18F-FDG, PET/MRI implementation in clinical practice, and the use of radiomics and machine learning. This article provides an overview of the use of 18F-FDG PET/CT in various clinical scenarios of head–neck squamous cell carcinoma, ranging from initial staging to treatment-response assessment, and post-therapy follow-up, with a focus on the current evidence, debated issues, and innovative applications. Methodological aspects and the most frequent pitfalls in head–neck imaging interpretation are described. In the initial work-up, 18F-FDG PET/CT is recommended in patients with metastatic cervical lymphadenectomy and occult primary tumor; moreover, it is a well-established imaging tool for detecting cervical nodal involvement, distant metastases, and synchronous primary tumors. Various 18F-FDG pre-treatment parameters show prognostic value in terms of disease progression and overall survival. In this scenario, an emerging role is played by radiomics and machine learning. For radiation-treatment planning, 18F-FDG PET/CT provides an accurate delineation of target volumes and treatment adaptation. Due to its high negative predictive value, 18F-FDG PET/CT, performed at least 12 weeks after the completion of chemoradiotherapy, can prevent unnecessary neck dissections. In addition to radiomics and machine learning, emerging applications include PET/MRI, which combines the high soft-tissue contrast of MRI with the metabolic information of PET, and the use of PET radiopharmaceuticals other than 18F-FDG, which can answer specific clinical needs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
130. Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
- Author
-
Sorice, Gian Pio, Cinti, Francesca, Leccisotti, Lucia, D'Amario, Domenico, Lorusso, Margherita, Guzzardi, Maria Angela, Mezza, Teresa, Cocchi, Camilla, Capece, Umberto, Ferraro, Pietro Manuel, Crea, Filippo, Giordano, Alessandro, Iozzo, Patricia, and Giaccari, Andrea
- Subjects
- *
INSULIN sensitivity , *CORONARY artery disease , *COMPUTED tomography , *POSITRON emission tomography , *DAPAGLIFLOZIN - Abstract
Introduction: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been shown to have beneficial effects on various cardiovascular (CV) outcomes in patients with type 2 diabetes (T2D) in primary prevention and in those with a high CV risk profile. However, the mechanism(s) responsible for these CV benefits remain elusive and unexplained. The aim of the DAPAHEART study will be to demonstrate that treatment with SGLT-2 inhibitors is associated with greater myocardial insulin sensitivity in patients with T2D, and to determine whether this improvement can be attributed to a decrease in whole-body (and tissue-specific) insulin resistance and to increased myocardial perfusion and/or glucose uptake. We will also determine whether there is an appreciable degree of improvement in myocardial-wall conditions subtended by affected and non-affected coronary vessels, and if this relates to changes in left ventricular function. Methods: The DAPAHEART trial will be a phase III, single-center, randomized, two-arm, parallel-group, double-blind, placebo-controlled study. A cohort of 52 T2D patients with stable coronary artery disease (without any previous history of myocardial infarction, with or without previous percutaneous coronary intervention), with suboptimal glycemic control (glycated hemoglobin [HbA1c] 7–8.5%) on their current standard of care anti-hyperglycemic regimen, will be randomized in a 1:1 ratio to dapagliflozin or placebo. The primary outcome is to detect changes in myocardial glucose uptake from baseline to 4 weeks after treatment initiation. The main secondary outcome will be changes in myocardial blood flow, as measured by 13N-ammonia positron emission tomography/computed tomography (PET/CT). Other outcomes include cardiac function, glucose uptake in skeletal muscle, adipose tissue, liver, brain and kidney, as assessed by fluorodeoxyglucose (FDG) PET-CT imaging during hyperinsulinemic-euglycemic clamp; pericardial, subcutaneous and visceral fat, and browning as observed on CT images during FDG PET-CT studies; systemic insulin sensitivity, as assessed by hyperinsulinemic-euglycemic clamp, glycemic control, urinary glucose output; and microbiota modification. Discussion: SGLT-2 inhibitors, in addition to their insulin-independent plasma glucose-lowering effect, are able to directly (substrate availability, fuel utilization, insulin sensitivity) as well as indirectly (cardiac after-load reduction, decreased risk factors for heart failure) affect myocardial functions. Our study will provide novel insights into how these drugs exert CV protection in a diabetic population. Trial registration: EudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
131. Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production.
- Author
-
Capece, Umberto, Pavanello, Chiara, Cinti, Francesca, Leccisotti, Lucia, Mezza, Teresa, Ciccarelli, Gea, Moffa, Simona, Di Giuseppe, Gianfranco, Soldovieri, Laura, Brunetti, Michela, Giordano, Alessandro, Giaccari, Andrea, Calabresi, Laura, and Ossoli, Alice
- Subjects
- *
NITRIC oxide , *LDL cholesterol , *HDL cholesterol , *BLOOD lipids , *HIGH density lipoproteins - Abstract
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown controversial results in modulating plasma lipids in clinical trials. Most studies found slight increases in high-density lipoprotein (HDL) cholesterol but few have provided evidence on HDL functionality with disappointing results. However, there is broad agreement that these drugs provide cardiovascular protection through several mechanisms. Our group demonstrated that dapagliflozin improves myocardial flow reserve (MFR) in patients with type 2 diabetes (T2D) with coronary artery disease (CAD). The underlying mechanisms are still unknown, although in vitro studies have suggested the involvement of nitric oxide (NO). Aim: To investigate changes in HDL-mediated modulation of NO production with dapagliflozin and whether there is an association with MFR. Methods: Sixteen patients with CAD-T2D were enrolled and randomized 1:1 to dapagliflozin or placebo for 4 weeks. Blood samples were collected before and after treatment for each group. The ability of HDL to stimulate NO production in endothelial cells was tested in vitro by incubating human umbilical vein endothelial cells (HUVEC) with apoB-depleted (apoB-D) serum of these patients. The production of NO was assessed by fluorescent assay, and results were expressed as fold versus untreated cells. Results: Change in HDL-mediated NO production remained similar in dapagliflozin and placebo group, even after adjustment for confounders. There were no significant correlations between HDL-mediated NO production and MFR either at baseline or after treatment. No changes were found in HDL cholesterol in either group, while low-density lipoprotein cholesterol (LDL cholesterol) significantly decreased compared to baseline only in treatment group (p = 0.043). Conclusions: In patients with T2D-CAD, beneficial effects of dapagliflozin on coronary microcirculation seem to be unrelated to HDL functions. However, HDL capacity to stimulate NO production is not impaired at baseline; thus, the effect of drug treatments would be negligible. To conclude, we can assume that HDL-independent molecular pathways are involved in the improvement of MFR in this population. Trial Registration: EudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
132. The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study.
- Author
-
Caldarella, Carmelo, Cocciolillo, Fabrizio, Taralli, Silvia, Lorusso, Margherita, Scolozzi, Valentina, Pizzuto, Daniele Antonio, Calcagni, Maria Lucia, Rufini, Vittoria, Guido, Davide, Palluzzi, Fernando, Giacò, Luciano, Giordano, Alessandro, and Leccisotti, Lucia
- Subjects
- *
SCIENTIFIC observation , *HEALTH outcome assessment , *RETROSPECTIVE studies , *TUMOR classification , *RADIOPHARMACEUTICALS , *POSITRON emission tomography , *DESCRIPTIVE statistics , *DEOXY sugars , *COMPUTED tomography , *STAY-at-home orders , *DATA analysis software - Abstract
Purpose : To investigate whether the COVID-19 pandemic and national lockdown had an impact on the extent of cancer disease at FDG PET/CT staging as surrogate marker. Methods: Retrospective observational study including cancer patients submitted to FDG PET/CT staging from June 1 to October 31, 2020, and June 1 to October 31, 2019, respectively. Data regarding primary tumour, nodal (N) status and number of involved nodal stations, and presence and number of distant metastases (M) were collected. Each scan was classified in limited vs advanced status. Data were aggregated across the study population and tumour type. Bi-weekly frequencies of the observed events were analysed. Results: Six hundred eleven patients were included (240 in 2019 vs 371 in 2020, respectively). A significant increase of advanced disease patients (rate 1.56, P < 0.001), N + or M + patients (rate 1.84 and 2.09, respectively, P < 0.001), and patients with a greater number of involved N stations or M (rate 2.01 and 2.06, respectively, P < 0.001) were found in 2020 compared with data of 2019. Analysis by tumour type showed a significant increase of advanced disease in lymphoma and lung cancer in 2020 compared with 2019 (P < 0.001). In addition, a significant increase of nodal involvement was found in lung, gastro-intestinal, and breast cancers, as well as in lymphoma patients (P < 0.02). A significant increase of distant metastases was found in lung cancers (P = 0.002). Conclusion: Cancer patients with advanced disease at FDG PET/CT staging increased in 2020 compared with 2019, following the national lockdown due to the COVID-19 pandemic, 1.5-fold with a significant increase of patients with N or M involvement. Targeted health interventions are needed to mitigate the effects of the pandemic on patient outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
133. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.
- Author
-
Naoumovaa RP, Kindler H, Lecisotti L, Mongillo M, Khan MT, Neuwirth C, Seed M, Holvoet P, Betteridge J, Camici PG, Naoumova, Rossi P, Kindler, Heiko, Leccisotti, Lucia, Mongillo, Marco, Khan, Muhammad T, Neuwirth, Clare, Seed, Mary, Holvoet, Paul, Betteridge, John, and Camici, Paolo G
- Abstract
Objectives: This study's aim was to examine whether treatment with pioglitazone, added to conventional lipid-lowering therapy, would improve myocardial glucose utilization (MGU) and blood flow (MBF) in nondiabetic patients with familial combined hyperlipidemia (FCHL).Background: Thiazolidinediones were found to improve insulin sensitivity and MGU in type 2 diabetes and MBF in Mexican Americans with insulin resistance. Familial combined hyperlipidemia is a complex genetic disorder conferring a high risk of premature coronary artery disease, characterized by high serum cholesterol and/or triglyceride, low high-density lipoprotein (HDL) cholesterol, and insulin resistance.Methods: We undertook a randomized, double-blind, placebo-controlled study in 26 patients with FCHL, treated with pioglitazone or matching placebo 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks. Positron emission tomography was used to measure MBF at rest and during adenosine-induced hyperemia and MGU during euglycemic hyperinsulinemic clamp at baseline and after treatment.Results: Whereas no change was observed in the placebo group after treatment, patients receiving pioglitazone showed a significant increase in whole body glucose disposal (3.93 +/- 1.59 mg/kg/min to 5.24 +/- 1.65 mg/kg/min; p = 0.004) and MGU (0.62 +/- 0.26 micromol/g/min to 0.81 +/- 0.14 micromol/g/min; p = 0.0007), accompanied by a significant improvement in resting MBF (1.11 +/- 0.20 ml/min/g to 1.25 +/- 0.21 ml/min/g; p = 0.008). Furthermore, in the pioglitazone group HDL cholesterol (+28%; p = 0.003) and adiponectin (+156.2%; p = 0.0001) were increased and plasma insulin (-35%; p = 0.017) was reduced.Conclusions: In patients with FCHL treated with conventional lipid-lowering therapy, the addition of pioglitazone led to significant improvements in MGU and MBF, with a favorable effect on blood lipid and metabolic parameters. (A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia; http://www.controlled-trials.com/mrct/trial/230761/ISRCTN78563659; ISRCTN78563659). [ABSTRACT FROM AUTHOR]- Published
- 2007
134. EANM consensus document on the use of [ 18 F]FDG PET/CT in fever and inflammation of unknown origin.
- Author
-
Hess S, Noriega-Álvarez E, Leccisotti L, Treglia G, Albano D, Roivainen A, Glaudemans AWJM, and Gheysens O
- Subjects
- Humans, Consensus, Nuclear Medicine, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography standards, Inflammation diagnostic imaging, Fever of Unknown Origin diagnostic imaging
- Abstract
Purpose: Patients with fever and inflammation of unknown origin (FUO/IUO) are clinically challenging due to variable clinical presentations with nonspecific symptoms and many differential diagnoses. Positron emission tomography/computed tomography (PET/CT) with 2-deoxy-2-[
18 F]fluoro-D-glucose ([18 F]FDG) is increasingly used in FUO and IUO, but the optimal diagnostic strategy remains controversial. This consensus document aims to assist clinicians and nuclear medicine specialists in the appropriate use of [18 F]FDG-PET/CT in FUO and IUO based on current evidence., Methods: A working group created by the EANM infection and inflammation committee performed a systematic literature search based on PICOs with "patients with FUO/IUO" as population, "[18 F]FDG-PET/CT" as intervention, and several outcomes including pre-scan characteristics, scan protocol, diagnostic yield, impact on management, prognosis, and cost-effectiveness., Results: We included 68 articles published from 2001 to 2023: 9 systematic reviews, 49 original papers on general adult populations, and 10 original papers on specific populations. All papers were analysed and included in the evidence-based recommendations., Conclusion: FUO and IUO remains a clinical challenge and [18 F]FDG PET/CT has a definite role in the diagnostic pathway with an overall diagnostic yield or helpfulness in 50-60% of patients. A positive scan is often contributory by directly guiding treatment or subsequent diagnostic procedure. However, a negative scan may be equally important by excluding focal disease and predicting a favorable prognosis. Similar results are obtained in specific populations such as ICU-patients, children and HIV-patients., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
135. Breast Relapse of Pediatric B-Cell Acute Lymphoblastic Leukemia After CAR-T Therapy Detected by 18 F-FDG PET/CT.
- Author
-
Perrone E, Taralli S, Pagliara D, Larocca LM, Vinti L, and Leccisotti L
- Subjects
- Humans, Female, Child, Neoplasm Recurrence, Local diagnostic imaging, Neoplasm Recurrence, Local pathology, Breast Neoplasms diagnostic imaging, Breast Neoplasms therapy, Breast Neoplasms pathology, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography methods, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnostic imaging
- Abstract
Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignancy. Medullary and extramedullary disease relapse is a well-known occurrence in B-ALL pediatric patients treated with standard chemo-immunotherapy and, more recently, with chimeric antigen receptor (CAR)-T cell therapy.
18 F-Fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) emerges as a sensitive imaging tool for detecting disease relapse at extra-medullary sites, with only limited literature evidence in the CAR-T therapy setting., Case Report: In a 12-year-old female treated with CAR-T therapy for B-ALL relapse,18 F-FDG PET/CT scan performed for surveillance, after disease remission, detected a solitary and clinically occult relapse in the breast parenchyma that was histologically confirmed., Conclusion: At our knowledge, this is the first report about a pediatric B-ALL patient with a solitary and occult breast relapse after CAR-T therapy, early discovered by18 F-FDG PET/CT during disease monitoring., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
136. Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.
- Author
-
Cinti F, Leccisotti L, Sorice GP, Capece U, D'Amario D, Lorusso M, Gugliandolo S, Morciano C, Guarneri A, Guzzardi MA, Mezza T, Capotosti A, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, and Giaccari A
- Subjects
- Humans, Adipose Tissue metabolism, Epicardial Adipose Tissue, Glucose metabolism, Inflammation drug therapy, Prospective Studies, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 drug therapy, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
Objective: We recently demonstrated that treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) leads to an increase in myocardial flow reserve in patients with type 2 diabetes (T2D) with stable coronary artery disease (CAD). The mechanism by which this occurs is, however, unclear. One of the risk factors for cardiovascular disease is inflammation of epicardial adipose tissue (EAT). Since the latter is often increased in type 2 diabetes patients, it could play a role in coronary microvascular dysfunction. It is also well known that SGLT-2i modify adipose tissue metabolism. We aimed to investigate the effects of the SGLT-2i dapagliflozin on metabolism and visceral and subcutaneous adipose tissue thickness in T2D patients with stable coronary artery disease and to verify whether these changes could explain observed changes in myocardial flow., Methods: We performed a single-center, prospective, randomized, double-blind, controlled clinical trial with 14 T2D patients randomized 1:1 to SGLT-2i dapagliflozin (10 mg daily) or placebo. The thickness of visceral (epicardial, mediastinal, perirenal) and subcutaneous adipose tissue and glucose uptake were assessed at baseline and 4 weeks after treatment initiation by 2-deoxy-2-[
18 F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography during hyperinsulinemic euglycemic clamp., Results: The two groups were well-matched for baseline characteristics (age, diabetes duration, HbA1c, BMI, renal and heart function). Dapagliflozin treatment significantly reduced EAT thickness by 19% (p = 0.03). There was a significant 21.6% reduction in EAT glucose uptake during euglycemic hyperinsulinemic clamp in the dapagliflozin group compared with the placebo group (p = 0.014). There were no significant effects on adipose tissue thickness/metabolism in the other depots explored., Conclusions: SGLT-2 inhibition selectively reduces EAT thickness and EAT glucose uptake in T2D patients, suggesting a reduction of EAT inflammation. This could explain the observed increase in myocardial flow reserve, providing new insights into SGLT-2i cardiovascular benefits., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
137. Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.
- Author
-
Leccisotti L, Maccora D, Malafronte R, D'Alò F, Maiolo E, Annunziata S, Rufini V, Giordano A, and Hohaus S
- Subjects
- Humans, Adult, Middle Aged, Aged, Aged, 80 and over, Tumor Burden, Fluorodeoxyglucose F18, Retrospective Studies, Time-to-Treatment, Watchful Waiting, Prognosis, Positron Emission Tomography Computed Tomography, Lymphoma, Follicular therapy
- Abstract
Purpose: Asymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW). Prediction of the time to treatment (TTT) is still a challenge. We investigated the prognostic value of baseline total metabolic tumour volume (TMTV) and whole-body total lesion glycolysis (WB-TLG) to predict TTT in patients with FL on WW., Methods: We conducted a retrospective study of 54 patients with FL (grade 1-3a) diagnosed between June 2013 and December 2019, staged with FDG PET/CT, and managed on WW. Median age was 62 years (range 34-85), stage was advanced (III-IV) in 57%, and FLIPI score was intermediate to high (≥ 2) in 52% of the patients., Results: The median TMTV and WB-TLG were 7.1 and 43.3, respectively. With a median follow-up of 59 months, 41% of patients started immuno-chemotherapy. The optimal cut-points to identify patients with TTT within 24 months were 14 for TMTV (AUC 0.70; 95% CI 51-88) and 64 for WB-TLG (AUC 0.71; 95% CI 52-89) (p < 0.005). The probability of not having started treatment within 24 months was 87% for TMTV < 14 and 53% for TMTV ≥ 14 (p < 0.005). TMTV was independent of the FLIPI score for TTT prediction. Patients with both FLIPI ≥ 2 and TMTV ≥ 14 had only an 18% probability of not having started treatment at 36 months, while this probability was 75% in patients with TMTV < 14., Conclusion: Metabolic tumour volume parameters may add information to clinical scores to better predict TTT and better stratify patients for interventional studies., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
138. Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
- Author
-
Leccisotti L, Cinti F, Sorice GP, D'Amario D, Lorusso M, Guzzardi MA, Mezza T, Gugliandolo S, Cocchi C, Capece U, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, and Giaccari A
- Subjects
- Benzhydryl Compounds, Blood Glucose metabolism, Glucosides, Humans, Positron Emission Tomography Computed Tomography, Prospective Studies, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 drug therapy, Heart Failure drug therapy, Sodium-Glucose Transporter 2 Inhibitors adverse effects
- Abstract
Objective: Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates for heart failure (HF). However, the mechanisms behind these benefits are not fully understood. This study was performed to investigate the effects of the SGLT-2i dapagliflozin on myocardial perfusion and glucose metabolism in patients with T2D and stable coronary artery disease (coronary stenosis ≥ 30% and < 80%), with or without previous percutaneous coronary intervention (> 6 months) but no HF., Methods: This was a single-center, prospective, randomized, double-blind, controlled clinical trial including 16 patients with T2D randomized to SGLT-2i dapagliflozin (10 mg daily) or placebo. The primary outcome was to detect changes in myocardial glucose uptake (MGU) from baseline to 4 weeks after treatment initiation by [(18)F]2-deoxy-2-fluoro-D-glucose (FDG) PET/CT during hyperinsulinemic euglycemic clamp. The main secondary outcome was to assess whether the hypothetical changes in MGU were associated with changes in myocardial blood flow (MBF) and myocardial flow reserve (MFR) measured by
13 N-ammonia PET/CT. The study was registered at eudract.ema.europa.eu (EudraCT No. 2016-003614-27) and ClinicalTrials.gov (NCT03313752)., Results: 16 patients were randomized to dapagliflozin (n = 8) or placebo (n = 8). The groups were well-matched for baseline characteristics (age, diabetes duration, HbA1c, renal and heart function). There was no significant change in MGU during euglycemic hyperinsulinemic clamp in the dapagliflozin group (2.22 ± 0.59 vs 1.92 ± 0.42 μmol/100 g/min, p = 0.41) compared with the placebo group (2.00 ± 0.55 vs 1.60 ± 0.45 μmol/100 g/min, p = 0.5). Dapagliflozin significantly improved MFR (2.56 ± 0.26 vs 3.59 ± 0.35 p = 0.006 compared with the placebo group 2.34 ± 0.21 vs 2.38 ± 0.24 p = 0.81; pint = 0.001) associated with a reduction in resting MBF corrected for cardiac workload (p = 0.005; pint = 0.045). A trend toward an increase in stress MBF was also detected (p = 0.054)., Conclusions: SGLT-2 inhibition increases MFR in T2D patients. We provide new insight into SGLT-2i CV benefits, as our data show that patients on SGLT-2i are more resistant to the detrimental effects of obstructive coronary atherosclerosis due to increased MFR, probably caused by an improvement in coronary microvascular dysfunction. Trial registration EudraCT No. 2016-003614-27; ClinicalTrials.gov Identifier: NCT03313752., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
139. Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
- Author
-
Galli E, Sorà F, Hohaus S, Bellesi S, Autore F, Metafuni E, Innocenti I, Marra J, Fresa A, Limongiello MA, Giammarco S, Leccisotti L, Guarneri A, Chiusolo P, Laurenti L, Teofili L, Piccirillo N, Bacigalupo A, and Sica S
- Subjects
- Antigens, CD19, Humans, Immunotherapy, Adoptive, T-Lymphocytes, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Lymphoma, B-Cell therapy
- Published
- 2022
- Full Text
- View/download PDF
140. Cavernous Hemangioma: A Potential Pitfall at Delayed 18F-FDG PET/CT Scan.
- Author
-
Scolozzi V, Giancipoli RG, Macciomei MC, Vigna L, and Leccisotti L
- Subjects
- Aged, Female, Humans, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Radiopharmaceuticals, Fluorodeoxyglucose F18, Hemangioma, Cavernous
- Abstract
Abstract: We report the case of a 72-year-old woman who underwent neoadjuvant chemotherapy, right quadrantectomy (invasive ductal carcinoma, G3, pT2pN1pMx), and adjuvant radiotherapy. Two years later, a follow-up CT revealed a hepatic nodule of approximately 1 cm suspected for metastasis. 18F-FDG PET/CT was performed for restaging. Standard total-body 18F-FDG PET/CT acquisition showed no abnormal 18F-FDG uptake in the hepatic nodule. A delayed 18F-FDG PET/CT acquisition of upper abdomen was performed at 180 minutes postradiopharmaceutical injection and showed increased 18F-FDG uptake in the hepatic nodule. After nodule resection, the histological examination proved a cavernous hemangioma., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
141. The prognostic role of FDG PET/CT before combined radio-chemotherapy in anal cancer patients.
- Author
-
Leccisotti L, Manfrida S, Barone R, Ripani D, Tagliaferri L, Masiello V, Privitera V, Gambacorta MA, Rufini V, Valentini V, and Giordano A
- Subjects
- Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Anus Neoplasms diagnostic imaging, Anus Neoplasms therapy, Chemoradiotherapy, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography
- Abstract
Objective: We assessed the prognostic value of several FDG PET/CT parameters, measured within the primary tumor and the involved lymph nodes, before definitive radio-chemotherapy (RCT) in anal cancer patients., Methods: Anal cancer patients with positive baseline FDG PET/CT who underwent definitive RCT from May 2011 to February 2018 were retrospectively assessed. Primary tumour (T)-SUVmax, T-SUVpeak, T-SUVmean, T-MTV, T-TLG, whole-body (WB) MTV, and WB-TLG were measured. Kaplan-Meier curves, Cox-regression analysis, and logistic regression machine-learning technique were used to test for associations between clinical data, metabolic parameters, and outcomes as overall survival (OS), disease-specific survival (DSS), metastatic-free survival (MFS), disease-free survival (DFS), local relapse-free survival (LRFS), and colostomy-free survival (CFS)., Results: Fifty-nine patients were included in the study. Median follow-up was 28 months. Higher pre-treatment WB-MTV, T-TLG, and WB-TLG were associated with worse OS (p = 0.025, 0.021, and 0.02, respectively). PET parameters resulted also statistically significant for DSS, DFS, and CFS (p = 0.032, 0.043, 9 × 10
-4 for WB-TLG). Cox analysis showed that PET parameters are significant predictors of OS, DSS, DFS, CFS, and LRFS. On multivariate analysis, age, stage, T-SUVpeak, WB-MTV, and T-TLG resulted significantly related to OS. A further stratification for patients with advanced stage (cT3-4 any N or any cT, N + ) showed that MTV and TLG, measured within the primary tumor and the involved nodes, are significantly higher in patients with a worse prognosis. In this subgroup, cut-off values of T- and WB-TLG as well as T- and WB-MTV showed a statistically significant correlation with clinical outcomes., Conclusions: Pre-treatment metabolic parameters measured within the primary tumor and the involved nodes may represent additional new biomarkers for estimating prognosis in anal cancer patients, especially in advanced stage patients.- Published
- 2020
- Full Text
- View/download PDF
142. Clinical relevance of PET myocardial blood flow quantification.
- Author
-
Leccisotti L, Lavalle M, and Giordano A
- Subjects
- Coronary Artery Disease diagnostic imaging, Coronary Artery Disease physiopathology, Humans, Coronary Circulation, Myocardial Perfusion Imaging methods, Positron-Emission Tomography methods
- Abstract
Until a few years ago, myocardial perfusion imaging (MPI) using positron-emission tomography (PET) and the absolute quantification of myocardial blood flow (MBF) was limited to research institutions. Following an increase in the number of PET scanner installations and in the availability of perfusion tracers that do not have to be produced by an on-site cyclotron and commercial software for MBF quantification, a more widespread clinical use of MBF quantification with PET can be expected. This article aims to provide a comprehensive overview of the advantages of MBF quantification with PET highlighting the potential applications in several clinical settings, from patients with cardiovascular risk factors and early coronary artery disease (CAD) to patients with multi-vessel or myocardial disease. Finally, using current evidence, the independent and incremental prognostic information of MBF quantification with PET in addition to the visual interpretation of MPI will also be described.
- Published
- 2016
143. ¹⁸F-fluoro-deoxy-glucose focal uptake in very small pulmonary nodules: fact or artifact? Case reports.
- Author
-
Calcagni ML, Taralli S, Maggi F, Rufini V, Treglia G, Leccisotti L, Bonomo L, and Giordano A
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Squamous Cell pathology, False Negative Reactions, False Positive Reactions, Fatal Outcome, Female, Humans, Lung Neoplasms pathology, Male, Multiple Pulmonary Nodules pathology, Solitary Pulmonary Nodule pathology, Tumor Burden, Carcinoma, Squamous Cell diagnostic imaging, Fluorodeoxyglucose F18, Lung Neoplasms diagnostic imaging, Multimodal Imaging, Multiple Pulmonary Nodules diagnostic imaging, Positron-Emission Tomography, Radiopharmaceuticals, Solitary Pulmonary Nodule diagnostic imaging, Tomography, X-Ray Computed
- Abstract
Background: 18F-fluoro-deoxy-glucose (18 F-FDG) positron emission tomography integrated/combined with computed tomography (PET-CT) provides the best diagnostic results in the metabolic characterization of undetermined solid pulmonary nodules. The diagnostic performance of 18 F-FDG is similar for nodules measuring at least 1 cm and for larger masses, but few data exist for nodules smaller than 1 cm., Case Presentation: We report five cases of oncologic patients showing focal lung 18 F-FDG uptake on PET-CT in nodules smaller than 1 cm. We also discuss the most common causes of 18 F-FDG false-positive and false-negative results in the pulmonary parenchyma.In patient 1, contrast-enhanced CT performed 10 days before PET-CT did not show any abnormality in the site of uptake; in patient 2, high-resolution CT performed 1 month after PET showed a bronchiole filled with dense material interpreted as a mucoid impaction; in patient 3, contrast-enhanced CT performed 15 days before PET-CT did not identify any nodules; in patients 4 and 5, contrast-enhanced CT revealed a nodule smaller than 1 cm which could not be characterized. The 18 F-FDG uptake at follow-up confirmed the malignant nature of pulmonary nodules smaller than 1 cm which were undetectable, misinterpreted, not recognized or undetermined at contrast-enhanced CT., Conclusion: In all five oncologic patients, 18 F-FDG was able to metabolically characterize as malignant those nodules smaller than 1 cm, underlining that: 18 F-FDG uptake is not only a function of tumor size but it is strongly related to the tumor biology; functional alterations may precede morphologic abnormalities. In the oncologic population, especially in higher-risk patients, PET can be performed even when the nodules are smaller than 1 cm, because it might give an earlier characterization and, sometimes, could guide in the identification of alterations missed on CT.
- Published
- 2012
- Full Text
- View/download PDF
144. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow.
- Author
-
McIntyre CW, Burton JO, Selby NM, Leccisotti L, Korsheed S, Baker CS, and Camici PG
- Subjects
- Acute Disease, Cross-Over Studies, Echocardiography, Humans, Middle Aged, Oxygen Radioisotopes, Positron-Emission Tomography, Coronary Circulation, Kidney Failure, Chronic therapy, Myocardial Ischemia diagnostic imaging, Myocardial Ischemia etiology, Renal Dialysis adverse effects
- Abstract
Background and Objectives: Hemodialysis is associated with hemodynamic instability, acute cardiac ischemia, and the development of regional wall motion abnormalities (RWMAs). This study used serial intradialytic H(2)(15)O positron emission tomography scanning to confirm that the development of dialysis-induced RWMAs was associated with reduction in myocardial blood flow (MBF)., Design, Setting, Participants, & Measurements: Four prevalent hemodialysis patients without angiographically significant coronary artery disease had measurements of MBF during standard hemodialysis and biofeedback dialysis. All patients underwent serial measurements of MBF using positron emission tomography. Concurrent echocardiography was used to assess left ventricular function and the development of RWMAs. Hemodynamic variables were measured using continuous pulse wave analysis., Results: Mean prehemodialysis MBF was within the normal range. Global MBF was acutely reduced during hemodialysis. Segmental MBF was reduced to a significantly greater extent in areas that developed RWMAs compared with those that did not. Not all regions with reduced MBF were functionally affected, but a reduction in myocardial blood flow of >30% from baseline was significantly associated with the development of RWMAs. No significant differences in hemodynamic tolerability, RWMA development, or MBF between dialysis modalities were observed., Conclusions: Hemodialysis is associated with repetitive myocardial ischemia, which, in the absence of coronary artery disease, may be due to coronary microvascular dysfunction. Stress-induced segmental left ventricular dysfunction correlates with matched reduction in MBF. Functional poststress recovery is consistent with myocardial stunning induced by hemodialysis. This process may be important in the development of heart failure in long-term hemodialysis patients.
- Published
- 2008
- Full Text
- View/download PDF
145. Positron emission tomography in the staging of esophageal cancer.
- Author
-
Leccisotti L
- Subjects
- Humans, Lymphatic Metastasis, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms pathology, Fluorodeoxyglucose F18, Neoplasm Staging methods, Positron-Emission Tomography, Radiopharmaceuticals
- Abstract
Accurate staging of patients with esophageal cancer (EC) is essential for selection of appropriate treatment and to predict prognosis. In recent years, positron emission tomography using the positron emitting glucose analogue 18F- fluorodeoxyglucose (FDG-PET) has emerged as a particularly useful adjunct to anatomical imaging modalities as computed tomography (CT) and endoscopic ultrasonography (EUS). In the initial staging of EC the additional value of FDG-PET is its ability to identify distant metastases (stage IV disease), excluding patients from unnecessary surgery. The combination of FDG-PET and endoscopic ultrasonography with fine-needle aspiration (EUS-FNA) has been suggested as the most effective strategy for preoperative EC staging.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.